molecules-logo

Journal Browser

Journal Browser

Recent Advances and Perspectives in Cancer Drug Design

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Chemical Biology".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 1870

Special Issue Editors


E-Mail Website
Guest Editor
College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China
Interests: bioinformatics; machine learning; metagenomics

E-Mail Website
Guest Editor
Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL 33612, USA
Interests: computational genomics
School of Computer Science and Engineering, Central South University, Changsha 410075, China
Interests: bioinformatics; systems biology; biomedical data mining; protein structure and function; ncRNA interactions and functions; drug discovery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer is one of the leading causes of death worldwide. The design of therapeutic drugs has become increasingly urgent and is a trend from the perspective of structural biology and molecular physics. Despite the advances in cancer biology and the continuous discovery of novel therapeutic targets, the development of effective new cancer drugs remains challenging due to the higher failure rate. Traditional drug discovery methods can be labor-intensive and time-consuming. Computational drug design, including structure-based and AI-based, has emerged as a powerful and promising technology for faster, cheaper, and more effective drug discovery.

In this Special Issue, the subtopics include, but are not limited to: novel understanding of cancer drugs; anticancer drug target prediction; approaches, tools and databases for drug discovery, design, and synthesis; machine learning methods for integrating multi-level omics data; statistical methods for integrating multi-level omics data; cancer drug sensitivity and resistance.

Dr. Liang Cheng
Dr. Mingxiang Teng
Dr. Lei Deng
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • anticancer drug
  • drug target
  • structure-based drug discovery
  • artificial intelligence (AI) based drug discovery
  • multi-level omics data
  • drug sensitivity
  • drug resistance

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 1414 KiB  
Article
Optimization of Bifunctional Antisense Oligonucleotides for Regulation of Mutually Exclusive Alternative Splicing of PKM Gene
by Natalia Bartyś, Anna Pasternak and Jolanta Lisowiec-Wąchnicka
Molecules 2022, 27(17), 5682; https://doi.org/10.3390/molecules27175682 - 3 Sep 2022
Cited by 1 | Viewed by 1464
Abstract
Oligonucleotide tools, as modulators of alternative splicing, have been extensively studied, giving a rise to new therapeutic approaches. In this article, we report detailed research on the optimization of bifunctional antisense oligonucleotides (BASOs), which are targeted towards interactions with hnRNP A1 protein. We [...] Read more.
Oligonucleotide tools, as modulators of alternative splicing, have been extensively studied, giving a rise to new therapeutic approaches. In this article, we report detailed research on the optimization of bifunctional antisense oligonucleotides (BASOs), which are targeted towards interactions with hnRNP A1 protein. We performed a binding screening assay, Kd determination, and UV melting experiments to select sequences that can be used as a high potency binding platform for hnRNP A1. Newly designed BASOs were applied to regulate the mutually exclusive alternative splicing of the PKM gene. Our studies demonstrate that at least three repetitions of regulatory sequence are necessary to increase expression of the PKM1 isoform. On the other hand, PKM2 expression can be inhibited by a lower number of regulatory sequences. Importantly, a novel branched type of BASOs was developed, which significantly increased the efficiency of splicing modulation. Herein, we provide new insights into BASOs design and show, for the first time, the possibility to regulate mutually exclusive alternative splicing via BASOs. Full article
(This article belongs to the Special Issue Recent Advances and Perspectives in Cancer Drug Design)
Show Figures

Figure 1

Back to TopTop